Clinical trial

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

NCT00746941

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record mefloquine Normalized identity: mefloquineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2009-01-01

PhasePHASE1 / PHASE2

Conditions

Progressive Multifocal Leukoencephalopathyverified · MONDO: progressive multifocal leukoencephalopathy

Interventions

mefloquineDRUG · verified · RxNorm: mefloquine

Sponsors & collaborators

Biogenlead sponsor

Elan Pharmaceuticalscollaborator

Mapped research locations

New YorkNew York, United States1 BostonMassachusetts, United States1 ChicagoIllinois, United States1 BaltimoreMaryland, United States1 St LouisMissouri, United States1 MadridSpain1 BarcelonaSpain1 BerlinGermany1 MilanItaly1 HamburgGermany1 São PauloBrazil1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00746941 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.